PF-04957325   Click here for help

GtoPdb Ligand ID: 9659

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PF-04957325 is a selective inhibitor of PDE8 [3] that is a useful chemical probe for studying the biological function of PDE8. It is compound 1-38 in patent WO2016030345 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 136.11
Molecular weight 400.1
XLogP -0.23
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Nc1nc(nc2c1nnn2CC1OCCN(C1)Cc1nccs1)C(F)(F)F
Isomeric SMILES Nc1nc(nc2c1nnn2C[C@@H]1OCCN(C1)Cc1nccs1)C(F)(F)F
InChI InChI=1S/C14H15F3N8OS/c15-14(16,17)13-20-11(18)10-12(21-13)25(23-22-10)6-8-5-24(2-3-26-8)7-9-19-1-4-27-9/h1,4,8H,2-3,5-7H2,(H2,18,20,21)/t8-/m1/s1
1. Basole CP, Nguyen RK, Lamothe K, Vang A, Clark R, Baillie GS, Epstein PM, Brocke S. (2017)
PDE8 controls CD4+ T cell motility through the PDE8A-Raf-1 kinase signaling complex.
Cell Signal, 40: 62-72. [PMID:28851628]
2. María del Mar Cuadrado T, Garcia OAM, Oyarzabel SJ, Rabal GMO. (2016)
Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases.
Patent number: WO2016030345. Assignee: Fundación Para La Investigación Médica Aplicada. Priority date: 26/08/2014. Publication date: 03/03/2016.
3. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. (2014)
Advances in targeting cyclic nucleotide phosphodiesterases.
Nat Rev Drug Discov, 13 (4): 290-314. [PMID:24687066]